TCG Crossover Acquires 9.9% Stake in Editas Medicine, Inc. (EDIT) via New Position

On June 3, 2026, TCG Crossover GP III, LLC, along with TCG Crossover Fund III, L.P. and Chen Yu, filed a Schedule 13G disclosing a new 9.9% stake in Editas Medicine, Inc. (EDIT). The reporting persons acquired 15,798,999 shares of common stock, which includes 11,111,111 shares of record and 4,687,888 shares underlying common stock warrants exercisable within 60 days. The filing notes that an additional 6,423,223 shares subject to warrants were excluded from the beneficial ownership calculation due to a 9.99% blocker provision (Beneficial Ownership Limitation). The acquisition followed an underwritten offering by the issuer that closed on May 27, 2026. Chen Yu, as the sole managing member of TCG Crossover GP III, shares voting and dispositive power over the securities. The reporting persons certified that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer.